Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TEK | Q02763 | 7/20 | 0.44 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.38 |
| ▸ | RAF1 | P04049 | 2/20 | 0.38 |
| ▸ | MAPK12 | P53778 | 2/20 | 0.38 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.38 |
| ▸ | ABL1 | P00519 | 2/20 | 0.36 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.36 |
| ▸ | BCR | P11274 | 2/20 | 0.36 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.35 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.33 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4177413 | 0.83 | NPY5R (0.37) | MAPK13RAF1MAPK12MAPK11MAPK14 | |
| SCHEMBL4182605 | 0.76 | AURKA (0.45) | MAPK13RAF1MAPK12MAPK11MAPK14 | |
| SCHEMBL4171248 | 0.76 | HDAC8 (0.34) | TEKMAPK13RAF1MAPK12MAPK11 | |
| SCHEMBL4180853 | 0.74 | KCNA5 (0.40) | CYP1A1CYP1A2CYP1B1ALDH1A1HPGD | |
| SCHEMBL4171121 | 0.72 | ABCB1 (0.48) | ABCB1CYP1A2ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL4172618 | 0.66 | KCNA5 (0.48) | CYP1A2ALDH1A1HPGDSMN1; SMN2HSD17B10 | |
| SCHEMBL4170892 | 0.64 | TUBB4A (0.42) | ABCB1ALDH1A1 | |
| SCHEMBL27449121 | 0.63 | CYP17A1 (0.57) | CYP1A2ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL22307327 | 0.63 | AURKA (0.50) | CYP1A2ALDH1A1 | |
| SCHEMBL6257420 | 0.63 | AURKA (0.47) | MAPK13RAF1MAPK12MAPK11MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090318438-A1 | Heterocyclic compounds and their use as anticancer agents | CHEN XIAOLING | 2009-12-24 | — | — | US | disclosed |
| US-20090048301-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTICANCER AGENTS | IMCLONE SYSTEMS INCORPORATED (US) | 2009-02-19 | — | — | US | disclosed |
| WO-2005004818-A2 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTICANCER AGENTS | IMCLONE SYSTEMS INCORPORATED (US) | 2005-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048301-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTICANCER AGENTS | TP53, MCL1, VHL | TEK 3690/4885MAPK13 2691/4885RAF1 595/4885 |
| US-20090318438-A1 | Heterocyclic compounds and their use as anticancer agents | TP53, MCL1, VHL | TEK 3690/4885MAPK13 2691/4885RAF1 595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.